New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
10:07 EDTSNSS, NMM, CAB, ATHL, ARIA, REPH, HOLI, BMRN, AEO, RSPP, CSTM, ATW, ALEOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARIAD (ARIA) coverage transitioned with a Neutral at UBS... Allete (ALE) initiated with a Neutral at JPMorgan... American Eagle (AEO) initiated with a Fair Value at CRT Capital... Athlon Energy (ATHL) initiated with a Buy at Mizuho... Atwood Oceanics (ATW) initiated with a Hold at Deutsche Bank... BioMarin (BMRN) coverage transitioned with a Buy at UBS... Cabela's (CAB) initiated with a Neutral at Goldman... Constellium (CSTM) initiated with a Buy at Sterne Agee... Hollysys Automation (HOLI) initiated with a Buy at Goldman... Navios Maritime Partners (NMM) initiated with a Buy at Jefferies... RSP Permian (RSPP) initiated with a Buy at Mizuho... Recro Pharma (REPH) initiated with a Buy at Aegis... Sunesis (SNSS) initiated with a Buy at UBS.
News For ARIA;ALE;AEO;ATHL;ATW;BMRN;CAB;CSTM;HOLI;NMM;RSPP;REPH;SNSS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 24, 2015
10:01 EDTATWOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:22 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
08:10 EDTHOLIHollysys Automation awarded contract for Chinese power plant
Subscribe for More Information
07:37 EDTARIAARIAD announces approval of Iclusig in Israel
ARIAD Pharmaceuticals and Medison Pharma announced that the Israeli Ministry of Health has granted regulatory approval for Iclusig, ponatinib, in Israel for adult patients with: Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation Philadelphia chromosome-positive acute lymphoblastic leukaemia who are resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation. ARIAD submitted its application for Iclusig to the Israeli Ministry of Health in June 2014. Commercial launch of Iclusig is expected to occur in Q2.
March 23, 2015
16:39 EDTATWAtwood Oceanics initiated with a Neutral at Susquehanna
Subscribe for More Information
10:00 EDTNMMOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:16 EDTATWHoward Weil to hold a conference
Subscribe for More Information
07:15 EDTHOLICredit Suisse to hold a conference
18th Annual Asian Investment Conference is being held in Hong Kong on March 23-27.
06:07 EDTNMMNavios Maritime Partners upgraded to Buy from Hold at Deutsche Bank
Subscribe for More Information
March 18, 2015
10:21 EDTRSPPHigh option volume stocks:
Subscribe for More Information
10:00 EDTRSPPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:45 EDTRSPPRSP Permian downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
06:02 EDTRSPPRSP Permian 9M share Spot Secondary priced at $25.80
Subscribe for More Information
March 17, 2015
16:34 EDTRSPPRSP Permian files to sell 5M shares of common stock
Barclays is acting as the sole underwriter for the offering.
16:26 EDTRSPPRSP Permian files to sell 4.6M shares of common stock for holders
07:53 EDTAEOMatson American Eagle Jack Henry named triple play at Oppenheimer
Subscribe for More Information
07:18 EDTBMRNMyriad Genetics announces collaboration expansion with BioMarin
Myriad Genetics (MYGN) announced an expansion of the company's collaboration with BioMarin Pharmaceutical (BMRN). Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive to talazoparib. Financial terms were not disclosed.
07:08 EDTALEAllete resumed with a Neutral at JPMorgan
Price target lowered to $53 from $56.
07:03 EDTRSPPRSP Permian reports Q4 production volumes up 106% YoY
Subscribe for More Information
07:01 EDTRSPPRSP Permian reports Q4 adj. EPS 20c, consensus 23c
Reports Q4 revenue $79.45M, consensus $83.28M.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use